Triad warfare against biofilms: disrupting quorum sensing, nanotechnology-driven precision, and host immunomodulation to conquer antimicrobial resistance.

Biofilm-associated infections pose a major global health threat due to their inherent resistance to conventional antibiotics, mediated by quorum sensing (QS), extracellular polymeric substances (EPS), persister cells, and immune evasion mechanisms. In this review, we propose the “Triad Warfare” strategy, integrating quorum-sensing inhibition (QSI), nanotechnology-enabled targeted drug delivery, and host-directed immunomodulation to synergistically disrupt biofilms while minimizing the risk of antimicrobial resistance (AMR). Specifically, QSI-mediated EPS disruption enhances nanoparticle penetration, facilitating controlled release of antimicrobial agents, while immunomodulators potentiate macrophage and neutrophil activity to clear residual bacterial populations, including metabolically dormant persisters. We provide a comparative analysis of natural and synthetic QS inhibitors, surface-modified nanoparticles (e.g., PEGylated AgNPs), and immunotherapeutic approaches (macrophage polarization, NET modulation, cytokine delivery), highlighting their efficacy, translational challenges, and clinical trial updates (Phase 1–2). Recent metabolic stimulation strategies (e.g., mannitol with aminoglycosides) and CRISPR-guided antimicrobials are also discussed for persister eradication. Furthermore, AI-driven anti-biofilm drug discovery using datasets such as AntiBiofilmDB, ChEMBL, and PubChem is evaluated for predictive design of combinatorial therapeutics. Collectively, this review emphasizes the mechanistic synergy, translational feasibility, and adaptive optimization of the triad approach, providing a roadmap for the development of next-generation anti-biofilm therapies with minimized resistance potential.